31
views
0
recommends
+1 Recommend
1 collections
    0
    shares

      Call for Papers: Current Management of Duodenal Neoplasia

      Submit here before December 31, 2024

      About Digestion: 3.0 Impact Factor I 7.9 CiteScore I 0.891 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition)

      other
      a , a , a , b , c , d , e , f , g , h , i , j , k , l , m , a , n , o , p , q , r , s , t , u , v , w , x , y , z , A , d , B , C , D , E , a , F , G , H , I , J , K , L , M , N , O , P , Q , R , S , T , U , V , a , h , W , X , j , d , Y , g , a , Z , α , β , γ , d , δ , ε , x , a , ζ , g , η , a , θ , ι , Y , λ , μ , ι , ξ , π , σ , τ , j , a , a , a , c , n , a , h , φ , χ , w , W , d , O , ψ , Γ , a ,
      Liver Cancer
      S. Karger AG
      Primary liver cancer, Hepatocellular carcinoma, Guidelines, China, Diagnosis, Treatment

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Primary liver cancer, of which around 75–85% is hepatocellular carcinoma in China, is the fourth most common malignancy and the second leading cause of tumor-related death, thereby posing a significant threat to the life and health of the Chinese people.

          Summary

          Since the publication of Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China in June 2017, which were updated by the National Health Commission in December 2019, additional high-quality evidence has emerged from researchers worldwide regarding the diagnosis, staging, and treatment of liver cancer, that requires the guidelines to be updated again. The new edition (2022 Edition) was written by more than 100 experts in the field of liver cancer in China, which not only reflects the real-world situation in China but also may reshape the nationwide diagnosis and treatment of liver cancer.

          Key Messages

          The new guideline aims to encourage the implementation of evidence-based practice and improve the national average 5-year survival rate for patients with liver cancer, as proposed in the “Health China 2030 Blueprint.”

          Related collections

          Most cited references286

          • Record: found
          • Abstract: found
          • Article: not found

          Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

          This article provides a status report on the global burden of cancer worldwide using the GLOBOCAN 2018 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer, with a focus on geographic variability across 20 world regions. There will be an estimated 18.1 million new cancer cases (17.0 million excluding nonmelanoma skin cancer) and 9.6 million cancer deaths (9.5 million excluding nonmelanoma skin cancer) in 2018. In both sexes combined, lung cancer is the most commonly diagnosed cancer (11.6% of the total cases) and the leading cause of cancer death (18.4% of the total cancer deaths), closely followed by female breast cancer (11.6%), prostate cancer (7.1%), and colorectal cancer (6.1%) for incidence and colorectal cancer (9.2%), stomach cancer (8.2%), and liver cancer (8.2%) for mortality. Lung cancer is the most frequent cancer and the leading cause of cancer death among males, followed by prostate and colorectal cancer (for incidence) and liver and stomach cancer (for mortality). Among females, breast cancer is the most commonly diagnosed cancer and the leading cause of cancer death, followed by colorectal and lung cancer (for incidence), and vice versa (for mortality); cervical cancer ranks fourth for both incidence and mortality. The most frequently diagnosed cancer and the leading cause of cancer death, however, substantially vary across countries and within each country depending on the degree of economic development and associated social and life style factors. It is noteworthy that high-quality cancer registry data, the basis for planning and implementing evidence-based cancer control programs, are not available in most low- and middle-income countries. The Global Initiative for Cancer Registry Development is an international partnership that supports better estimation, as well as the collection and use of local data, to prioritize and evaluate national cancer control efforts. CA: A Cancer Journal for Clinicians 2018;0:1-31. © 2018 American Cancer Society.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Cancer statistics in China, 2015.

            With increasing incidence and mortality, cancer is the leading cause of death in China and is a major public health problem. Because of China's massive population (1.37 billion), previous national incidence and mortality estimates have been limited to small samples of the population using data from the 1990s or based on a specific year. With high-quality data from an additional number of population-based registries now available through the National Central Cancer Registry of China, the authors analyzed data from 72 local, population-based cancer registries (2009-2011), representing 6.5% of the population, to estimate the number of new cases and cancer deaths for 2015. Data from 22 registries were used for trend analyses (2000-2011). The results indicated that an estimated 4292,000 new cancer cases and 2814,000 cancer deaths would occur in China in 2015, with lung cancer being the most common incident cancer and the leading cause of cancer death. Stomach, esophageal, and liver cancers were also commonly diagnosed and were identified as leading causes of cancer death. Residents of rural areas had significantly higher age-standardized (Segi population) incidence and mortality rates for all cancers combined than urban residents (213.6 per 100,000 vs 191.5 per 100,000 for incidence; 149.0 per 100,000 vs 109.5 per 100,000 for mortality, respectively). For all cancers combined, the incidence rates were stable during 2000 through 2011 for males (+0.2% per year; P = .1), whereas they increased significantly (+2.2% per year; P < .05) among females. In contrast, the mortality rates since 2006 have decreased significantly for both males (-1.4% per year; P < .05) and females (-1.1% per year; P < .05). Many of the estimated cancer cases and deaths can be prevented through reducing the prevalence of risk factors, while increasing the effectiveness of clinical care delivery, particularly for those living in rural areas and in disadvantaged populations.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

                Bookmark

                Author and article information

                Journal
                Liver Cancer
                Liver Cancer
                LIC
                LIC
                Liver Cancer
                S. Karger AG (Basel, Switzerland )
                2235-1795
                1664-5553
                5 April 2023
                October 2023
                : 12
                : 5
                : 405-444
                Affiliations
                [a ]Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China
                [b ]Department of Pathology, The Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China
                [c ]Department of Radiology, Zhongshan Hospital, Fudan University, Shanghai, China
                [d ]The Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China
                [e ]Institute of Hepatobiliary Surgery, Southwest Hospital, Third Military Medical University, Chongqing, China
                [f ]Department of General Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China
                [g ]Department of Liver Surgery, West China Hospital of Sichuan University, Chengdu, China
                [h ]Department of Hepatobiliary Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China
                [i ]Department of Liver Diseases and Digestive Interventional Radiology, Xijing Hospital, Fourth Military Medical University, Xi’an, China
                [j ]Department of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, China
                [k ]Department of Interventional Radiology, Chinese PLA General Hospital, Beijing, China
                [l ]Department of Interventional Radiology, The Tumor Hospital of Harbin Medical University, Harbin, China
                [m ]Department of Interventional Oncology, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China
                [n ]Department of Radiation Oncology, Zhongshan Hospital, Fudan University, Shanghai, China
                [o ]Department of Interventional Ultrasound, Chinese PLA General Hospital, Beijing, China
                [p ]Department of Radiology, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China
                [q ]Editorial Department of Chinese Journal of Digestive Surgery, Chongqing, China
                [r ]Department of Radiology, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China
                [s ]Department of Ultrasound, Zhongshan Hospital, Fudan University, Shanghai, China
                [t ]Department of Infectious Diseases, State Key Laboratory of Organ Failure Research, Nanfang Hospital, Southern Medical University, Guangzhou, China
                [u ]Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China
                [v ]Department of Pathology, Tumor Prevention and Treatment Center, Sun Yat-sen University, Guangzhou, China
                [w ]Department of Hepatobiliary and Pancreatic Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
                [x ]Department of Integrative Medicine, Zhongshan Hospital, Fudan University, Shanghai, China
                [y ]Department of Radiology, West China Hospital of Sichuan University, Chengdu, China
                [z ]Department of Hematology, Ruijin Hospital North, Shanghai Jiao Tong University School of Medicine, Shanghai, China
                [A ]Department of Integrated Therapy, Fudan University Shanghai Cancer Center, Shanghai, China
                [B ]Department of Hepatobiliary and Spleenary Surgery, The Affiliated Shengjing Hospital, China Medical University, Shenyang, China
                [C ]Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
                [D ]Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China
                [E ]Graduate School, Beijing University of Chinese Medicine, Beijing, China
                [F ]Department of Hepatic Surgery, Affiliated Provincial Hospital, Anhui Medical University, Hefei, China
                [G ]Department of Oncology, West China Hospital, Sichuan University, Chengdu, China
                [H ]Department of General Surgery, Qilu Hospital, Shandong University, Jinan, China
                [I ]The First Hospital of Lanzhou University, Lanzhou, China
                [J ]Department of Nuclear Medicine, The First Hospital of China Medical University, Shenyang, China
                [K ]Department of Radiation Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
                [L ]Department of Oncology, Peking University International Hospital, Beijing, China
                [M ]Changhai Hospital of Traditional Chinese Medicine, Second Military Medical University, Shanghai, China
                [N ]Department of Oncology, Zhongshan Hospital, Fudan University, Shanghai, China
                [O ]Department of Medical Oncology, PLA Cancer Center, Nanjing Bayi Hospital, Nanjing, China
                [P ]Institute and Hospital of Hepatobiliary Surgery of Chinese PLA, Chinese PLA Medical School, Chinese PLA General Hospital, Beijing, China
                [Q ]Department of General Surgery, The First Hospital of Jilin University, Jilin, China
                [R ]Department of Liver Surgery, Peking Union Medical College (PUMC) Hospital, PUMC and Chinese Academy of Medical Sciences, Beijing, China
                [S ]Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
                [T ]Department of Hepatobiliary Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, China
                [U ]Department of Interventional Radiology the First Affiliated Hospital of Xinjiang Medical University, Urumqi, China
                [V ]Department of Nuclear Medicine, Zhongshan Hospital, Fudan University, Shanghai, China
                [W ]Department of Hepatobiliary Surgery, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
                [X ]Department of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical University, Xi’an, China
                [Y ]Department of Hepatic Surgery, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China
                [Z ]Department of Infectious Diseases, Xiangya Hospital, Central South University, Changsha, China
                [α ]Department of Hepatobiliary Surgery, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China
                [β ]Department of Hepato-Pancreato-Biliary Surgery, Peking University Cancer Hospital and Institute, Beijing, China
                [γ ]Department of Gastrointestinal Oncology, Affiliated Hospital Cancer Center, Academy of Military Medical Sciences, Beijing, China
                [δ ]Department of Interventional Oncology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
                [ε ]Department of Hepatic Surgery and Interventional Radiology, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China
                [ζ ]Department of Hepatobiliary Surgery, Zhongshan Hospital of Xiamen University, Xiamen, China
                [η ]Department of Surgery, Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
                [θ ]Department of Hepatobiliary Surgery Institute, Southwest Hospital, Third Military Medical University, Chongqing, China
                [ι ]Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, ZhengZhou, China
                [λ ]Department of Gastrointestinal Medical Oncology, The Affiliated Tumor Hospital of Harbin Medical University, Harbin, China
                [μ ]Minimally Invasive Interventional Division, Liver Cancer Group, Sun Yat-Sen University Cancer Center, Guangzhou, China
                [ξ ]Department of Oncology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
                [π ]Department of General Surgery, Xiangya Hospital, Central South University, Changsha, China
                [σ ]Department of Hepatobiliary Surgery, Peking University People’s Hospital, Beijing, China
                [τ ]Department of Minimally Invasive Interventional Radiology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
                [φ ]Department of Abdominal Surgical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
                [χ ]Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
                [ψ ]Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing, China
                [Γ ]Department of Hepatobiliary and Pancreas Surgery, Beijing Tsinghua Changgung Hospital (BTCH), School of Clinical Medicine, Tsinghua University, Beijing, China
                Author notes

                Jian Zhou, Huichuan Sun, and Zheng Wang contributed equally to this work.

                Article
                530495
                10.1159/000530495
                10601883
                37901768
                0292dfb0-e911-441e-8b27-c308ce840f20
                © 2023 The Author(s). Published by S. Karger AG, Basel

                This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC) ( http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.

                History
                : 15 November 2022
                : 24 January 2023
                : 2023
                Page count
                Figures: 3, Tables: 1, References: 289, Pages: 40
                Funding
                This research received no external funding.
                Categories
                Guidelines

                primary liver cancer,hepatocellular carcinoma,guidelines,china,diagnosis,treatment

                Comments

                Comment on this article